caretrace.iopowered by▸healthparse
SearchCohort Builder
Tools▾
KOL FinderTerritoriesDrug Compare
AI Query
Browse▾
By stateBy specialty
Pricing
SearchCohort BuilderToolsKOL FinderTerritoriesDrug CompareAI QueryBrowseBy stateBy specialtyPricing
PROVIDER PROFILE · NPI 1730403841

Rebecca LapatingPA-C

PRACTICEHORNG MEDICAL ENTERPRISES INCSee all providers at this practice →
Physician AssistantIrvine, CAI
CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore
OIG/SAM exclusion screening, sanctions history
© 2026 CareTrace
PricingContactPrivacyTerms
MEDICARE UTILIZATION · PART B · 2024
Total beneficiaries
687
Unique beneficiaries
—
Total services
709
Distinct HCPCS
12
Medicare payment
$38K
Peer benchmark
Q1
Q2
Q3
Q4
Q5
Total Medicare services vs. 7,073 Physician Assistant providers in CA — top quintile (cohort median 224).
REFERRAL NETWORK

Where Rebecca Lapating's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 3 inbound referrers · 0 outbound destinations.

Receives referrals from
Inbound — who sends patients here
PhysicianPatientsVisits
Bryan Doonan
Family Practice · Newport Beach, CA
4168
Primex Clinical Laboratories Inc.
Clinical Laboratory · Van Nuys, CA
3768
Unilab Corporation
Clinical Laboratory · West Hills, CA
1116
Refers patients to
Outbound — where patients go next
No outbound pairs above the suppression threshold.
Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.
PRESCRIBING · PART D · 2024
Total Rx claims
233
Beneficiaries
—
Total drug cost
$2K
Distinct drugs
12
Brand share
52.8%
Top prescribed drugs
Amoxicillin/Potassium Clav32 claims
Cephalexin32 claims
Nitrofurantoin Monohyd/M-Cryst28 claims
Sulfamethoxazole/Trimethoprim28 claims
Nirmatrelvir/Ritonavir20 claims
QUALITY · MIPS · 2024
Final MIPS score
87.5
Quality
84.1
Cost
74.2
Improvement activities
40.0
Promoting interop.
100.0
Payment adjustment
0.53%
Group
INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024
No data available for this provider in 2024.